Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 4 of about 4   

Articles published

DVAX 23.58 -0.58 (-2.40%)
price chart
Andrew Gengos out, John Walker in as Neuraltus CEO
Andrew Gengos, who led Neuraltus Pharmaceuticals Inc. into a Phase II trial of its experimental treatment for Lou Gehrig's disease, has left the company. Veteran Bay Area biotech executive John Walker, Neuraltus' chairman, took over Aug. 15 as interim ...
Lonmin cuts platinum sales targets
�The company clearly needs a major refinancing and the share price has been very volatile as a consequence of a lot of uncertainty, including how long it takes to resolve the strike action and whether Xstrata may or may not participate in a rights ...
Related articles »  
3 Vaccine Companies With Upcoming Catalysts
Dynavax Technologies Corporation (NASDAQ:DVAX), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Related articles »  
2 $4 Biotech Stocks Making Strong Recent Moves
"Dynavax Technologies Corporation (NASDAQ:DVAX) is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases.